Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

Linda L Garland, L. A. Robinson, H. Wagner

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

Original languageEnglish (US)
Pages (from-to)69-100
Number of pages32
JournalChest Surgery Clinics of North America
Volume11
Issue number1
StatePublished - 2001
Externally publishedYes

Fingerprint

Non-Small Cell Lung Carcinoma
Poisons
Thorax
Therapeutics

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer. / Garland, Linda L; Robinson, L. A.; Wagner, H.

In: Chest Surgery Clinics of North America, Vol. 11, No. 1, 2001, p. 69-100.

Research output: Contribution to journalArticle

@article{106789b349a0497da1dc7026aede5649,
title = "Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer",
abstract = "Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.",
author = "Garland, {Linda L} and Robinson, {L. A.} and H. Wagner",
year = "2001",
language = "English (US)",
volume = "11",
pages = "69--100",
journal = "Thoracic Surgery Clinics",
issn = "1547-4127",
publisher = "W.B. Saunders Ltd",
number = "1",

}

TY - JOUR

T1 - Evaluation and management of patients with stage IIIA (N2) non-small-cell lung cancer

AU - Garland, Linda L

AU - Robinson, L. A.

AU - Wagner, H.

PY - 2001

Y1 - 2001

N2 - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

AB - Management of the stage IIIA (N2) patient remains one of the most controversial areas in thoracic oncology. The potential cur-ability of at least some of these patients has encourage the development of more complex, aggressive, and toxic multimodality treatment regimens.

UR - http://www.scopus.com/inward/record.url?scp=0035103952&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035103952&partnerID=8YFLogxK

M3 - Article

VL - 11

SP - 69

EP - 100

JO - Thoracic Surgery Clinics

JF - Thoracic Surgery Clinics

SN - 1547-4127

IS - 1

ER -